Goldman Sachs
ANAB icon

Goldman Sachs’s AnaptysBio ANAB Stock Holding History

Goldman Sachs’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-25,700
Closed -$666K – 6200
2021
Q2 		$666K Hold
25,700
– – ﹤0.01% 5040
2021
Q1 		$554K Buy
+25,700
New +$649K ﹤0.01% 5038

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs's ANAB Position: Q1 2026 in Review

Goldman Sachs reduced its AnaptysBio (ANAB) stake by 17% in Q1 2026, selling an estimated $3.56M and leaving 332,743 shares worth $18.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2511.

Goldman Sachs first reported a position in ANAB in Q2 2017 and has held it in 36 quarters since. The position peaked at $19.3M in Q4 2025. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

  • Goldman Sachs held 332,743 shares of AnaptysBio worth $18.5M as of Q1 2026.
  • Goldman Sachs sold 66,171 AnaptysBio shares in Q1 2026, an estimated $3.56M.
  • AnaptysBio made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2511 holding.
  • Goldman Sachs first reported a position in AnaptysBio in Q2 2017 and has held it in 36 quarters since.
  • Goldman Sachs's AnaptysBio position peaked at $19.3M in Q4 2025.
  • 207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.